Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Physics

Cancer Oncology

Medicine

Pathology

Internal Medicine

Show all topics

DOI

10.1016/s1470-2045(19)30277-3

License

publisher-specific-oa